These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850 [No Abstract] [Full Text] [Related]
9. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG; Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361 [TBL] [Abstract][Full Text] [Related]
10. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235 [TBL] [Abstract][Full Text] [Related]
11. [Problems of cardiovascular toxicity of coxibs and non-selective NSA]. Forejtová S Vnitr Lek; 2006; 52(7-8):677-85. PubMed ID: 16967608 [TBL] [Abstract][Full Text] [Related]
12. [Selective cyclooxygenase-2 inhibitors and the digestive tract]. Chaabouni H; Amouri A; Cheikh I; Kchaou M; Ouerghi H; Ben Mami N; Ben Ammar A Tunis Med; 2002 Aug; 80(8):427-33. PubMed ID: 12703120 [TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 inhibitors: what went wrong? James MJ; Cleland LG Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171 [TBL] [Abstract][Full Text] [Related]
14. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. Lamarque D Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340 [TBL] [Abstract][Full Text] [Related]
15. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Mukherjee D Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915 [TBL] [Abstract][Full Text] [Related]
16. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867 [TBL] [Abstract][Full Text] [Related]
17. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. Choi HK; Seeger JD; Kuntz KM Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759 [TBL] [Abstract][Full Text] [Related]
18. COX-2 selective inhibitors and heart health. Simon LS; White WB Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717 [TBL] [Abstract][Full Text] [Related]
19. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Mukherjee D Biochem Pharmacol; 2002 Mar; 63(5):817-21. PubMed ID: 11911832 [TBL] [Abstract][Full Text] [Related]
20. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. Davies NM; Jamali F J Pharm Pharm Sci; 2004 Oct; 7(3):332-6. PubMed ID: 15576013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]